These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 21611939)

  • 1. [Stimulant and non-stimulant medication in current and future therapy for ADHD].
    Franke AG; Konrad A; Lieb K; Huss M
    Fortschr Neurol Psychiatr; 2012 Mar; 80(3):130-40. PubMed ID: 21611939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB; Chae S; Patel A; Steinberg-Epstein R
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative pharmacological strategies for adult ADHD treatment: a systematic review.
    Buoli M; Serati M; Cahn W
    Expert Rev Neurother; 2016; 16(2):131-44. PubMed ID: 26693882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for ADHD.
    Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
    [No Abstract]   [Full Text] [Related]  

  • 7. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J; Sikirica V; Mathurin K
    BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological management of attention-deficit hyperactivity disorder.
    Reeves G; Schweitzer J
    Expert Opin Pharmacother; 2004 Jun; 5(6):1313-20. PubMed ID: 15163276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G; Newcorn JH
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
    Harstad E; Shults J; Barbaresi W; Bax A; Cacia J; Deavenport-Saman A; Friedman S; LaRosa A; Loe IM; Mittal S; Tulio S; Vanderbilt D; Blum NJ
    JAMA; 2021 May; 325(20):2067-2075. PubMed ID: 33946100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
    Jain R; Katic A
    Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for the treatment of attention-deficit/hyperactivity disorder.
    Pataki CS; Feinberg DT; McGough JJ
    Expert Opin Emerg Drugs; 2004 Nov; 9(2):293-302. PubMed ID: 15571486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
    Huang YS; Tsai MH
    CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E; Fogler JM; Hammerness PG
    JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs under investigation for attention-deficit hyperactivity disorder.
    Schweitzer JB; Holcomb HH
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1207-11. PubMed ID: 12211416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A; Hoo-Cardiel A; Lang P
    Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of dopaminergic and stimulant drugs for the treatment of depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2012 Feb; 50(2):11-4. PubMed ID: 22263621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.
    Fredriksen M; Halmøy A; Faraone SV; Haavik J
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):508-27. PubMed ID: 22917983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.